Response to Rituximab and Timeframe to Relapse in Rheumatoid Arthritis Patients

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska et al. · Arthritis & Rheumatism · 2006 · 1.1K citations

Medicine, Internal Medicine, Pharmacotherapy +13

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

James Edwards, Geraldine Cambridge · Lara D. Veeken · 2001 · 522 citations · Full text

Life Sciences, Immunology, Internal Medicine +16

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

Geraldine Cambridge, Maria Leandro, Jonathan Edwards et al. · Arthritis & Rheumatism · 2003 · 462 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

Shouvik Dass, Andy C. Rawstron, Edward M Vital et al. · Arthritis & Rheumatism · 2008 · 212 citations · Full text

Life Sciences, Immunology, Internal Medicine +16